DistantNews
Support us
First AI-designed vaccine enters clinical trials
🇬🇷 Greece /Health & Science

First AI-designed vaccine enters clinical trials

From Ta Nea · () Greek

Translated from Greek, summarized and contextualized by DistantNews.

At a glance

News Named sources Ongoing story
  • Researchers have developed the first vaccine designed by artificial intelligence, which is now in early clinical trials.
  • The AI-designed vaccine targets a 'superantigen' to provide broad protection against a family of viruses, including future mutations and animal-to-human transmissions.
  • Early trials in 39 people assessed safety, with a larger study of 200 participants to evaluate effectiveness, showing a 'moderate' immune response.

A groundbreaking vaccine, designed entirely by artificial intelligence, has entered the initial phase of human clinical trials, marking a significant leap in medical innovation. This novel approach aims to outpace the constant evolution of viruses, a challenge that has historically made vaccine development a reactive process.

We are always one step behind.

— Professor Jonathan HeeneyExplaining the challenge of developing vaccines against constantly mutating viruses.

Traditional vaccines are typically designed against a current strain of a virus. However, researchers at Cambridge University utilized AI to analyze genetic codes from various coronaviruses. The AI identified and designed a 'superantigen' capable of training the immune system to recognize and defend against an entire family of viruses. This broad-spectrum approach is intended to offer protection even if viruses mutate or jump from animals to humans.

to get ahead of the curve

— Professor Jonathan HeeneyDescribing the objective of creating vaccines that can anticipate and protect against future viral threats.

Professor Jonathan Heeney from Cambridge University explained the research's goal is to "get ahead of the curve" and create vaccines that can preemptively protect against future epidemics or pandemics. Heeney highlighted that this is the first time an AI-designed antigen is being tested in humans, calling the technology "amazing" and "beneficial for humanity."

This is the first time an antigen designed by AI is being tested in humans, calling the technology 'amazing' and 'beneficial for humanity.'

— Professor Jonathan HeeneyHighlighting the significance of the AI-driven vaccine design and its potential impact.

Initial clinical trials involving 39 participants focused on evaluating the vaccine's safety. A subsequent study with approximately 200 participants is expected to provide clearer insights into its effectiveness in stimulating the immune system. While the immune response observed in early stages was characterized as 'moderate,' the results have generated optimism among researchers. Professor Saul Faust from the University of Southampton, involved in the trials, described the AI design as having "clear potential" and being "particularly exciting" for developing vaccines against potentially pandemic viruses.

has clear potential and is particularly exciting.

— Professor Saul FaustCommenting on the promise of AI in designing vaccines, especially for potential pandemics involving mutating viruses.
DistantNews Editorial

Originally published by Ta Nea in Greek. Translated, summarized, and contextualized by our editorial team with added local perspective. Read our editorial standards.

More Stories

From Our Blog